Gender and strain contributions to the variability of buprenorphine-related respiratory toxicity in mice

Toxicology

Volumn 305, Issue , 2013, Pages 99-108

  Alhaddad, Hisham ^a,b   Cisternino, Salvatore ^a,b   Saubamea, Bruno ^a,b   Schlatter, Joel ^c   Chiadmi, Fouad ^c   Risède, Patricia ^a,b   Smirnova, Maria ^a,b   Cochois Guégan, Véronique ^a,b   Tournier, Nicolas ^d   Baud, Frédéric J ^a,b,e   Mégarbane, Bruno ^a,b,e  

^a FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL JEAN VERDIER   (France)

^d SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^e HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Blood brain barrier; Buprenorphine; Gender differences; P glycoprotein; Respiratory depression; Strain differences

Indexed keywords

BUPRENORPHINE; MULTIDRUG RESISTANCE PROTEIN; NORBUPRENORPHINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BODY PLETHYSMOGRAPHY; BRAIN PERFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG TRANSPORT; EXHALATION; FEMALE; INHALATION; LUNG MINUTE VOLUME; LUNG TOXICITY; LUNG VENTILATION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEX DIFFERENCE; STRAIN DIFFERENCE; SWISS WEBSTER MOUSE; WESTERN BLOTTING;

ANIMALS; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; BUPRENORPHINE; CAPILLARIES; CEREBROVASCULAR CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MICE; NARCOTICS; P-GLYCOPROTEIN; PLETHYSMOGRAPHY, WHOLE BODY; RESPIRATORY INSUFFICIENCY; SEX CHARACTERISTICS; SPECIES SPECIFICITY;

EID: 84873969079     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2013.01.013     Document Type: Article

References (46)

1. Albermann N., Schmitz-Winnenthal F.H., Z'Graggen K., Volk C., Hoffmann M.M., Haefeli W.E., Weiss J. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem. Pharmacol. 2005, 70:949-958.
2. Alhaddad H., Cisternino S., Declèves X., Tournier N., Schlatter J., Chiadmi F., Risède P., Smirnova M., Besengez C., Scherrmann J.M., Baud F.J., Mégarbane B. Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice. Crit. Care Med. 2012, 40:3215-3223.
3. Bartlett D.J.R., Tenney S.M. Control of breathing in experimental anemia. Respir. Physiol. 1970, 10:384-395.
4. Benet L.Z., Cummins C.L., Wu C.Y. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab. 2003, 4:393-398.
5. Brown S.M., Campbell S.D., Crafford A., Regina K.J., Holtzman M.J., Kharasch E.D. P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception. J. Pharmacol. Exp. Ther. 2012, 343:53-61.
6. Bonora M., Bernaudin J.F., Guernier C., Brahimi-Horn M.C. Ventilatory responses to hypercapnia and hypoxia in conscious cystic fibrosis knockout mice Cftr-/- Pediatr. Res. 2004, 55:738-746.
7. Cattelotte J., André P., Ouellet M., Bourasset F., Scherrmann J.M., Cisternino S. In situ mouse carotid perfusion model: glucose and cholesterol transport in the eye and brain. J. Cereb. Blood Flow Metab. 2008, 28:1449-1459.
8. Chen K.W., Berger C.C., Forde D.P., D'Adamo C., Weintraub E., Gandhi D. Benzodiazepine use and misuse among patients in a methadone program. BMC Psychiatry 2011, 11:90.
9. Chevillard L., Mégarbane B., Risède P., Baud F.J. Characteristics and comparative severity of respiratory response to toxic doses of fentanyl, methadone, morphine, and buprenorphine in rats. Toxicol. Lett. 2009, 191:327-340.
10. Cowan A., Lewis J.W., Macfarlane I.R. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol. 1977, 60:537-545.
11. Cowan A., Doxey J.C., Harry E.J. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br. J. Pharmacol. 1977, 60:547-554.
12. Cummins C.L., Wu C.Y., Benet L.Z. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin. Pharmacol. Ther. 2002, 72:474-489.
13. Dagenais C., Rousselle C., Pollack G.M., Scherrmann J.M. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein deficient mice. J. Cereb. Blood Flow Metab. 2000, 20:381-386.
14. Dahan A., Sarton E., Teppema L., Olievier C. Sex-related differences in the influence of morphine on ventilatory control in humans. Anesthesiology 1998, 88:903-913.
15. Dahan A., Yassen A., Bijl H., Romberg R., Sarton E., Teppema L., Olofsen E., Danhof M. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br. J. Anaesth. 2005, 94:825-834.
16. Gowing L., Ali R., White J.M. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst. Rev. 2009, CD002025.
17. Greenblatt D.J., von Moltke L.L. Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J. Clin. Pharmacol. 2008, 48:1350-1355.
18. Gueye P.N., Borron S.W., Risède P., Monier C., Buneaux F., Debray M., Baud F.J. Lack of effect of single high doses of buprenorphine on arterial blood gases in the rat. Toxicol. Sci. 2001, 62:148-154.
19. Hanada S., Snider N.T., Brunt E.M., Hollenberg P.F., Omary M.B. Gender dimorphic formation of mouse Mallory-Denk bodies and the role of xenobiotic metabolism and oxidative stress. Gastroenterology 2010, 138:1607-1617.
20. Hreiche R., Mégarbane B., Pirnay S., Borron S.W., Monier C., Risède P., Milan N., Descatoire V., Pessayre D., Baud F.J. Dexamethasone hepatic induction in rats subsequently treated with high dose buprenorphine does not lead to respiratory depression. Toxicol. Appl. Pharmacol. 2006, 217:352-362.
21. Huang P., Kehner G.B., Cowan A., Liu-Chen L.Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J. Pharmacol. Exp. Ther. 2001, 297:688-695.
22. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci. Int. 2001, 121:65-69.
23. Iribarne C., Picart D., Dréano Y., Bail J.P., Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 1997, 60:1953-1964.
24. Kacew S., Festing M.F. Role of rat strain in the differential sensitivity to pharmaceutical agents and naturally occurring substances. J. Toxicol. Environ. Health 1996, 47:1-30.
25. Kornstein S., Clayton A.H. Women's Mental Health: A Comprehensive Textbook 2002, The Guilford Press, New York.
26. Lifschitz A., Ballent M., Virkel G., Sallovitz J., Lanusse C. Sex-related differences in the gastrointestinal disposition of ivermectin in the rat: P-glycoprotein involvement and itraconazole modulation. J. Pharm. Pharmacol. 2006, 58:1055-1062.
27. Mégarbane B., Marie N., Pirnay S., Borron S.W., Gueye P.N., Risède P., Monier C., Noble F., Baud F.J. Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol. Appl. Pharmacol. 2006, 212:256-267.
28. Mégarbane B., Buisine A., Jacobs F., Résière D., Chevillard L., Vicaut E., Baud F.J. Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment. J. Subst. Abuse Treat. 2010, 38:403-407.
29. Moody D.E., Fang W.B., Morrison J., McCance-Katz E. Gender differences in pharmacokinetics of maintenance dosed buprenorphine. Drug Alcohol Depend. 2011, 118:479-483.
30. Nielsen S., Taylor D.A. The effect of buprenorphine and benzodiazepines on respiration in the rat. Drug Alcohol Depend. 2005, 79:95-101.
31. Ohtani M., Kotaki H., Nishitateno K., Sawada Y., Iga T. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J. Pharmacol. Exp. Ther. 1997, 281:428-433.
32. Parkinson A., Mudra D.R., Johnson C., Dwyer A., Carroll K.M. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol. Appl. Pharmacol. 2004, 15:193-209.
33. Pirnay S., Borron S.W., Giudicelli C.P., Tourneau J., Baud F.J., Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 2004, 99:978-988.
34. Schuetz E.G., Furuya K.N., Schuetz J.D. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J. Pharmacol. Exp. Ther. 1995, 275:1011-1018.
35. Schuetz E.G., Umbenhauer D.R., Yasuda K., Brimer C., Nguyen L., Relling M.V., Schuetz J.D., Schinkel A.H. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol. Pharmacol. 2000, 57:188-197.
36. Soldin O.P., Mattison D.R. Sex differences in pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 2009, 48:143-157.
37. Tallarida R., Murray R.B. Area under a curve: Simpson's rule and trapezoidal rule. Manual of Pharmacologic Calculations with Computer Programs 1981, 47-49. Springer-Verlag, New York. R. Tallarida, R.B. Murray (Eds.).
38. Tournier N., Declèves X., Saubaméa B., Scherrmann J.M., Cisternino S. Opioid transport by ATP-binding cassette transporters at the blood-brain barrier: implications for neuropsychopharmacology. Curr. Pharm. Des. 2011, 17:2829-2842.
39. Unger A., Jung E., Winklbaur B., Fischer G. Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine. J. Addict. Dis. 2010, 29:217-230.
40. Wolbold R., Klein K., Burk O., Nüssler A.K., Neuhaus P., Eichelbaum M., Schwab M., Zanger U.M. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003, 38:978-988.
41. Yassen A., Kan J., Olofsen E., Suidgeest E., Dahan A., Danhof M. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats. J. Pharmacol. Exp. Ther. 2006, 319:682-692.
42. Yousif S., Marie-Claire C., Roux F., Scherrmann J.M., Decleves X. Expression of drug transporters at the blood-brain barrier using an optimized isolated rat brain microvessel strategy. Brain Res. 2007, 1134:1-11.
43. Yousif S., Chaves C., Potin S., Margaill I., Scherrmann J.M., Declèves X. Induction of P-glycoprotein and Bcrp at the rat blood-brain barrier following a subchronic morphine treatment is mediated through NMDA/COX-2 activation. J. Neurochem. 2012, 123:491-503.
44. Yu Y., Zhang L., Yin X., Sun H., Uhl G.R., Wang J.B. Mu opioid receptor phosphorylation, desensitization, and ligand efficacy. J. Biol. Chem. 1997, 272:28869-28874.
45. Zuber R., Anzenbacherova E., Anzenbacher P. Cytochromes P450 and experimental models of drug metabolism. J. Cell. Mol. Med. 2002, 6:189-198.
46. Zubieta J.K., Dannals R.F., Frost J.J. Gender and age differences on human brain mu-opioid receptor binding measured by PET. Am. J. Psychiatry 1999, 156:842-848.